These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 29783295)

  • 61. P4 medicine could transform healthcare, but payers and physicians are not yet convinced.
    Biotechnol Healthc; 2010; 7(3):7-8. PubMed ID: 22478823
    [No Abstract]   [Full Text] [Related]  

  • 62. Editorial: Managing healthcare transformation towards P5 medicine.
    Blobel B; Kalra D
    Front Med (Lausanne); 2023; 10():1244100. PubMed ID: 37692783
    [No Abstract]   [Full Text] [Related]  

  • 63. Conversations With the Editors: Stewardship in Genomic Medicine-Insights From Health Care Payers at the Forefront of Clinical Innovation and Partnerships.
    Smith HS; Sherman M; Cardeiro D
    Clin Ther; 2023 Aug; 45(8):690-694. PubMed ID: 37550140
    [No Abstract]   [Full Text] [Related]  

  • 64. Will comparative effectiveness research finally succeed?
    Blackstone EA; Fuhr JP; Ziernicki D
    Biotechnol Healthc; 2012; 9(3):22-6. PubMed ID: 23091431
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Experience With IVDR Implementation in Three Diagnostic Laboratories: Messages to EU Health Institutions, Diagnostic Healthcare Payers, and Authorities.
    Lubbers BR; Dombrink I; Kalina T; Hofmans M; Bruun MS; Stanworth SJ; Béné MC; Döhner K; Brüggemann M; Macintyre E; van Dongen JJM
    Hemasphere; 2023 Apr; 7(4):e865. PubMed ID: 36911048
    [No Abstract]   [Full Text] [Related]  

  • 66. Payers following FDA effort to integrate pharmacogenomics into drug development.
    Carlson B
    Biotechnol Healthc; 2004 Sep; 1(4):12-4. PubMed ID: 23393434
    [No Abstract]   [Full Text] [Related]  

  • 67. Preparing for Healthcare After COVID-19: New Challenges Facing Payers.
    Kuznar W
    Am Health Drug Benefits; 2020 Jun; 13(3):123-124. PubMed ID: 32699573
    [No Abstract]   [Full Text] [Related]  

  • 68. With injectable biologic therapies on the rise, payers face tough reimbursement issues.
    Biotechnol Healthc; 2010; 7(2):31. PubMed ID: 22478820
    [No Abstract]   [Full Text] [Related]  

  • 69. Implementing a Hybrid Model of Therapy is a Win for Therapists, Patients and Payers.
    Galin B
    Int J Sports Phys Ther; 2024; 19(1):1521-1522. PubMed ID: 38179579
    [No Abstract]   [Full Text] [Related]  

  • 70. Exploring the Perception of Value in Cancer Care: A Comparison of Patients, Providers, and Payers.
    Allen CJ; Greene AC; Joseph EA; Dunung R; Knotts CM; Chalikonda S; Bartlett DL
    Ann Surg Oncol; 2024 Jun; ():. PubMed ID: 38890198
    [No Abstract]   [Full Text] [Related]  

  • 71. Arming Providers and Payers with Treatment- and Value-Based Management Tools for Battling Cancer.
    Mitchell M
    Am Health Drug Benefits; 2015 Aug; 8(Spec Issue):42. PubMed ID: 26380629
    [No Abstract]   [Full Text] [Related]  

  • 72. Promise of translational medicine: An evidence-based therapeutics.
    Naidu MU
    Indian J Pharmacol; 2011 Apr; 43(2):103-4. PubMed ID: 21572640
    [No Abstract]   [Full Text] [Related]  

  • 73. Resources Available When Dealing With Commercial Payers.
    J Oncol Pract; 2005 Jul; 1(2):46. PubMed ID: 29447504
    [No Abstract]   [Full Text] [Related]  

  • 74. Driving forces behind the past and future emergence of personalized medicine.
    Steffen JA; Steffen JS
    J Pers Med; 2013 Jan; 3(1):14-22. PubMed ID: 25562408
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Diffusion of molecular diagnostic lung cancer tests: a survey of german oncologists.
    Steffen JA
    J Pers Med; 2014 Mar; 4(1):102-14. PubMed ID: 25562146
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Healthcare payers: a gate or translational bridge to personalized medicine?
    Canestaro WJ; Martell LA; Wassman ER; Schatzberg R
    Per Med; 2012 Jan; 9(1):73-84. PubMed ID: 29783295
    [TBL] [Abstract][Full Text] [Related]  

  • 77. PARC report: a perspective on the state of clinical pharmacogenomics testing.
    Eichmeyer J; Rogers S; Formea CM; Giri J; Jones JS; Schnettler E; Schmidlen T; Glogowski E; Kurz RN
    Pharmacogenomics; 2020 Jul; 21(11):809-820. PubMed ID: 32635876
    [TBL] [Abstract][Full Text] [Related]  

  • 78. What do providers, payers and patients need from comparative effectiveness research on diagnostics? The case of HER2/Neu testing in breast cancer.
    Trosman JR; Weldon CB; Schink JC; Gradishar WJ; Benson AB
    J Comp Eff Res; 2013 Jul; 2(4):461-77. PubMed ID: 24236686
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Payer view of personalized medicine.
    Pezalla EJ
    Am J Health Syst Pharm; 2016 Dec; 73(23):2007-2012. PubMed ID: 27864208
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Innovative payer engagement strategies: will the convergence lead to better value creation in personalized medicine?
    Akhmetov I; Bubnov RV
    EPMA J; 2017 Dec; 8(1):5-15. PubMed ID: 28228864
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.